Core A will provide endpoint analyses for experiments involving apoptosis in both cell culture systems and in animal and human tissues. Apoptosis analyses for cell culture will include bright field examination (LM) using Romanowsky-type dyes or polychrome stains and transmission electron microscopy (TEM). Apoptosis will be quantitated in animal and human colonic specimens using light microscopy. The core will be responsible for maintaining and testing flat mucosa from colon resections and from colonoscopies (from cancer patients, adenoma patients, and """"""""normal"""""""" patients). Tests would include measurements of apoptosis and specific proteins of interest to the project directors. We will use fluorochrome tags on secondary antibodies to detect specific proteins in conjunction with Leica Laser Scanning Confocal Microscopy (LSCM), or produce permanent slides using immunohistochemical procedures. By these approaches we will identify and quantify gene products of significance to the three projects, including proteins which may prove valuable as biomarkers of colon cancer risk (e.g. Hsp70, Cox-2, Gadd153, and others. Quality control studies will be performed to measure expression of potential biomarkers in each of the different regions of the colon of normal individuals as a basis for identifying abnormal expression in high risk individuals. The core will also measure expression of potential biomarkers in the normal appearing mucosa of cancer patients at various distances from the cancer. The core will establish, maintain, subclone and test apoptosis resistant colonic epithelial cell lines for altered gene expression. Cellular effects of chemopreventive agents, of other drugs and of transfections will be evaluated by microscopic methods applicable to the particular experimental situation. Procedures to be made available are ultrastructural cytochemistry (including cryosectioning), fluorescent apoptosis/necrosis assay, bright-field examination of cytospin preparations, semi-thin plastic sectioning, and paraffin embedding. The core will also assist in developing special microscopic procedures to answer specific questions that emerge as experimental data are obtained and analyzed. Two experienced research specialists will be available in the core to provide this assistance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA072008-04A1
Application #
6418173
Study Section
Project Start
1997-07-01
Project End
2005-12-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
4
Fiscal Year
2001
Total Cost
$130,479
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Raj, K P; Zell, J A; Rock, C L et al. (2013) Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. Br J Cancer 108:512-8
Rial, Nathaniel S; Zell, Jason A; Cohen, Alfred M et al. (2012) Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancer. Expert Rev Gastroenterol Hepatol 6:507-17
Laukaitis, Christina M; Erdman, Steven H; Gerner, Eugene W (2012) Chemoprevention in patients with genetic risk of colorectal cancers. Colorectal Cancer 1:225-240
Laukaitis, Christina M; Gerner, Eugene W (2011) DFMO: targeted risk reduction therapy for colorectal neoplasia. Best Pract Res Clin Gastroenterol 25:495-506
Zell, Jason A; Ziogas, Argyrios; Ignatenko, Natalia et al. (2009) Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clin Cancer Res 15:6208-16
Feldman, Rebecca; Martinez, Jesse D (2009) Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of EGFR. Biochim Biophys Acta 1793:1387-94
Gerner, Eugene W; Meyskens Jr, Frank L (2009) Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res 15:758-61
Rial, Nathaniel S; Lazennec, Gwendal; Prasad, Anil R et al. (2009) Regulation of deoxycholate induction of CXCL8 by the adenomatous polyposis coli gene in colorectal cancer. Int J Cancer 124:2270-80
Zell, Jason A; Pelot, Daniel; Chen, Wen-Pin et al. (2009) Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila) 2:209-12
Ashbeck, Erin L; Jacobs, Elizabeth T; Martínez, María Elena et al. (2009) Components of metabolic syndrome and metachronous colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 18:1134-43

Showing the most recent 10 out of 88 publications